Inactive Instrument

AMAG Pharmaceuticals, Inc.

AMAG

US00163U1060

Amag Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020

May 11, 2020 at 04:30 pm IST

AMAG Pharmaceuticals, Inc. announced earnings results for the first quarter ended March 31, 2020. For the first quarter, the company announced total revenue was USD 68.661 million compared to USD 75.804 million a year ago. Operating loss was USD 19.575 million compared to USD 117.697 million a year ago. Net loss was USD 24.491 million compared to USD 122.084 million a year ago. Basic loss per share from continuing operations was USD 0.72 compared to USD 3.54 a year ago.

Latest news about AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals, Inc. Files Submission in Response to the Food and Drug Administration’s Notice of Opportunity for A Hearing and Proposal to Withdraw Approval of Makena® (Hydroxyprogesterone Caproate Injection)	14/20/14	CI
AMAG Pharmaceuticals, Inc. Announces Management Changes	17/20/17	CI
AMAG Pharmaceuticals, Inc. Appoints Michael Porter as Chief Executive Officer	17/20/17	CI
AMAG Pharmaceuticals, Inc. Appoints Ozgur Kilic as Chief Financial Officer	17/20/17	CI
AMAG Pharmaceuticals, Inc.(NasdaqGS:AMAG) dropped from S&P 1000	13/20/13	CI
AMAG Pharmaceuticals, Inc.(NasdaqGS:AMAG) dropped from S&P Composite 1500	13/20/13	CI
AMAG Pharmaceuticals, Inc.(NasdaqGS:AMAG) dropped from S&P Global BMI Index	13/20/13	CI
AMAG Pharmaceuticals, Inc.(NasdaqGS:AMAG) dropped from S&P 600 Health Care	13/20/13	CI
AMAG Pharmaceuticals, Inc.(NasdaqGS:AMAG) dropped from S&P 600	13/20/13	CI
AMAG Pharmaceuticals, Inc.(NasdaqGS:AMAG) dropped from S&P TMI Index	13/20/13	CI
AMAG Pharmaceuticals, Inc.(NasdaqGM:AVM) dropped from Russell 2500 Index	13/20/13	CI
AMAG Pharmaceuticals, Inc.(NasdaqGM:AVM) dropped from Russell 2000 Value Index	13/20/13	CI
AMAG Pharmaceuticals, Inc.(NasdaqGM:AVM) dropped from Russell 2500 Value Index	13/20/13	CI
AMAG Pharmaceuticals, Inc.(NasdaqGM:AVM) dropped from Russell Small Cap Completeness Index	13/20/13	CI
AMAG Pharmaceuticals, Inc.(NasdaqGM:AVM) dropped from Russell 3000 Value Index	13/20/13	CI
AMAG Pharmaceuticals, Inc.(NasdaqGM:AVM) dropped from Russell 2000 Index	13/20/13	CI
AMAG Pharmaceuticals, Inc.(NasdaqGM:AVM) dropped from Russell 3000 Index	13/20/13	CI
AMAG Pharmaceuticals, Inc.(NasdaqGM:AVM) dropped from Russell Small Cap Comp Value Index	13/20/13	CI
AMAG Pharmaceuticals, Inc.(NasdaqGM:AVM) dropped from Russell 2000 Value-Dynamic Index	13/20/13	CI
AMAG Pharmaceuticals, Inc.(NasdaqGM:AVM) dropped from Russell 2500 Value-Dynamic Index	13/20/13	CI
AMAG Pharmaceuticals, Inc.(NasdaqGM:AVM) dropped from Russell 2500 Dynamic Index	13/20/13	CI
AMAG Pharmaceuticals, Inc.(NasdaqGM:AVM) dropped from Russell 3000E Index	13/20/13	CI
AMAG Pharmaceuticals, Inc.(NasdaqGM:AVM) dropped from Russell 3000E Value Index	13/20/13	CI
AMAG Pharmaceuticals, Inc.(NasdaqGM:AVM) dropped from Russell Microcap Index	13/20/13	CI
AMAG Pharmaceuticals, Inc.(NasdaqGM:AVM) dropped from Russell Microcap Value Index	13/20/13	CI

Chart AMAG Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

AMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company's segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women. Makena is a drug indicated to reduce the risk of preterm birth in women pregnant with a single baby having a history of singleton spontaneous preterm birth.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+39.57%	72TCr
NOVO NORDISK A/S	+34.28%	59TCr
JOHNSON & JOHNSON	-4.08%	37TCr
MERCK & CO., INC.	+20.25%	33TCr
ABBVIE INC.	+2.86%	28TCr
ASTRAZENECA PLC	+17.02%	24TCr
NOVARTIS AG	+9.31%	21TCr
ROCHE HOLDING AG	-5.07%	21TCr
PFIZER, INC.	-0.36%	17TCr

Other Pharmaceuticals